Red Blood Cells for Drug Delivery

2019-07-18 浏览次数：153次

项目基本情况

技术名称：	Red Blood Cells for Drug Delivery
技术类型：	Patented
所属行业：	Scientific Research, Technical Services
项目地点：	Germany, Switzerland
技术成熟度：	Ready for Mass-production
需求报价：	100.0万美元万美元

技术成果简介

技术成果简介：

Project description

Off-the-shelf, ready to use advanced therapies with Novel and Innovative proprietary cell lines for drug delivery that increases patients’ care at significantly reduced healthcare cost.

Rius Medical develops drug delivery devices cheaper than the competition so that individuals can afford healthcare. These are off-the-shelf, ready to use advanced therapies with Novel and Innovative proprietary cell lines for drug delivery. Best in class medication that increases patients’ healthcare at significantly reduced healthcare cost. Application in Rare Diseases, Oncology and Autoimmune Diseases like type 1 diabetes.

Economic rationale / Business Model

Healthcare cost is shooting up and payers (governments, insurance companies and patients) around the world are increasingly struggling to pay for innovative therapies. Biotech and Big pharma bring innovation that cost a fortune to patients. Well what we do at Rius Medical is develop drug delivery devices that are cheaper than the competition so that healthcare becomes affordable to individuals no matter what income they make and still we make a profit.

Rius Medical re-invents blood transfusion with ready-to-use, off-the-shelf enhanced red blood cells, doing more than simply carry Oxygen as cargo. Through the use of technology and cutting-edge science to accelerate cures for the world’s most life-threatening conditions, we aim to provide solutions for global healthcare’s biggest cost drivers by addressing Rare Diseases, Oncology and Autoimmune Diseases like type 1 diabetes, all within one platform technology.

Rius Medical mission is to make its highly innovative platform technology available to pharmaceutical and biotech partners to transport their drugs to patients alongside improving lifespan and efficacy while drastically reducing side effects.

Financing details

Project financing secured: EUR 0 million (0 %)

Financing source: Private

1. A Business Angel to invest 300.000 euro or more, provided that a lead Investor brings at least 30.000 euro equity capital.

2. medifundo Service Agreement for equity capital within medifundo’s network of Business Angels. medifundo seeks to raise 300.000 euro equity capital if not 600.000 euro.

3. angels4health for equity capital of up to 100.000 euro within angels4health network of Business Angels for at least a Convertible Loan of 30.000 euro at a discounted rate of 0,50 euro per share.

Existing or potential bottlenecks for the realisation of the project / Potential risks

Red blood cells for drug delivery is Phase III validated in acute lymphoblastic leukemia. Furthermore platform technologies offer lower risk investments, as they bring not only a growing portfolio of candidates, but through out-licensing, support the development of partnership programs. E.g. June 2019 SQZ Biotech and Erytech Pharma partnership to develop red blood cells for drug delivery. Rius Medical targets B2B partnership at 3 years with Erytech Pharma, Rubius Therapeutics and Novo Nordisk.

Project additional information

Rius Medical targets B2B partnerships at 3 years with Erytech Pharma, Rubius Therapeutics and Novo Nordisk if not Servier Laboratories. The partnership deals at 3 year are expected to bring 130 million euro revenue. This is aligned to Rius Medical mission of making its highly innovative platform technology available to pharmaceutical and biotech partners. With a 4 million euro pre-money valuation, Rius Medical is raising Series A funding of up to 1 million euro. An EXIT opportunity at 3 years for early investors investing up to 1 million euro results in 54 million euro financial benefit for FIVE products, if not 10,5 million euro financial benefit for TWO products being transformational improvements on market approved biopharmaceuticals.

项目资料：

单位和联系方式

更多项目推荐